Intensity Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• INT230-6 · Oncology
  INT230-6 is a dual-acting immunotherapy that combines a TLR9 agonist with doxorubicin to activate innate immunity and promote anti-tumor immune responses.

Phase 1 pipeline

• anti-CTLA-4 antibody

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Intensity Therapeutics, Inc. portfolio CI brief
• Intensity Therapeutics, Inc. pipeline updates RSS